Business context and reporting period
Filing identity: Although the request names Neurogene Inc., the supplied filing is Aquinox Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2017. The figures below are for Aquinox and its subsidiary, not Neurogene.
Aquinox was a clinical-stage pharmaceutical company with no revenue, focused on rosiptor (AQX-1125), an oral SHIP1 activator being developed for interstitial cystitis/bladder pain syndrome (IC/BPS). The filing covers the three and nine months ended September 30, 2017; balance-sheet comparisons are with December 31, 2016. Amounts below are U.S. dollars.
Financial results and liquidity
- Revenue: None to date.
- Operating expenses: Third-quarter R&D was $8.5 million, versus $6.1 million a year earlier; G&A was $3.6 million, versus $2.1 million. Nine-month R&D was $24.7 million, versus $20.3 million; G&A was $9.9 million, versus $5.9 million. Management attributed the increases primarily to greater Leadership 301 trial activity, personnel costs, and pre-commercial and market-assessment work.
- Net loss: Third-quarter loss was $11.8 million ($0.50 per share), compared with $8.1 million ($0.46 per share). Nine-month loss was $33.9 million ($1.45 per share), compared with $25.8 million ($1.48 per share). The lower nine-month loss per share despite a larger net loss reflects a higher weighted-average share count.
- Cash flow: Nine-month operating cash use was $33.1 million, compared with $21.2 million in 2016. Investing activities provided $47.5 million, mainly reflecting investment maturities; financing activities provided $0.4 million. Cash and cash equivalents increased $14.8 million to $47.1 million.
- Liquidity and balance sheet: Cash, cash equivalents and short-term investments totaled $119.7 million at September 30, 2017; working capital was $113.6 million. Total assets were $121.6 million, down from $154.4 million at year-end 2016, when the company also held $50.0 million of long-term investments. Total liabilities were $7.5 million, including $37,000 in capital lease obligations; the filing reports no material change in contractual commitments.
- Margins and debt: Operating or gross margins are not meaningful for a pre-revenue company. No material debt balance is reported; the disclosed capital lease obligation was small.
Material changes versus the prior comparable period
- Quarterly and nine-month operating expenses and net losses increased, primarily alongside expanded clinical activity and higher administrative costs.
- Nine-month operating cash use increased, which management attributed to higher expenses and payment timing for costs incurred in 2016.
- Interest income rose to $0.7 million for the first nine months from $0.4 million, reflecting higher cash and investment balances. No derivative liability remained at September 30, 2017.
- The 2016 comparative financing cash flow included $75.4 million of gross proceeds from a public offering; there was no comparable offering in the first nine months of 2017.
Outlook, commentary and risks
- Management expected existing capital resources to fund operations for at least the next 12 months, while also anticipating a need for substantial future financing. It warned that additional funding may be unavailable on acceptable terms and could dilute shareholders or constrain operations.
- Aquinox expected R&D spending and operating losses to increase as it advanced rosiptor. The Leadership 301 Phase 3 trial was underway; its planned primary endpoint measured change in maximum daily bladder pain at 12 weeks. Trial enrollment, data, and regulatory discussions were expected to inform the design and scale of further studies. The filing does not provide a clear expected date for Leadership 301 results.
- The company noted that the FDA planned an IC/BPS Advisory Committee meeting for December 7, 2017. Approval requirements, including the number and design of additional trials, remained uncertain.
- Key risks include clinical-trial delay or failure, the unvalidated SHIP1 target, potential safety issues, reliance on CROs and a limited number of contract manufacturers, regulatory uncertainty, competition, and the need for additional capital. The filing also disclosed animal toxicities involving severe gastrointestinal ulcerations in dogs and ocular-lens effects in some animals; clinical trials had generally shown tolerability, with gastrointestinal upset among the more common reported side effects.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. The company reported no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the filing belongs to Aquinox Pharmaceuticals, Inc., not Neurogene Inc., before relying on these figures.
- Check Leadership 301 enrollment, results timing, and any subsequent regulatory guidance on required IC/BPS trials.
- Assess cash runway against the company’s rising clinical spending and stated expectation of future financing.
- Review whether trial progress, safety findings, manufacturing capacity, or regulatory requirements have changed since the filing.
- Verify current share count and potential dilution from equity compensation or future financing.